Contributions
Abstract: EP1344
Type: ePoster
Abstract Category: Clinical aspects of MS - 5 Epidemiology
Background and objectives: Available epidemiological data suggest that the prevalence of multiple sclerosis (MS) in Spain is progressively increasing during the last four decades. The aim of this study was to estimate the actual prevalence rate of MS in the southeast of Spain.
Methods: This epidemiologic study was conducted in the city of San Vicente del Raspeig, located in the southeast of Spain, latitude 38° 23′, with a population of 56.715. April 10, 2017 was selected as the prevalence day. Case ascertainment included computerised primary care medical records system, the MS database of Alicante General Hospital, the district hospital that offers specialized care to MS patients and data from the MS patients´ association. 2010 McDonald´s criteria were used for the diagnosis of multiple sclerosis. Lublin criteria (2013 revisions) were used for MS phenotypes.
Results: A total of 58 patients (45 women, 13 men) had a confirmed diagnosis (Poser and 2010 McDonald´s criteria). The overall crude prevalence rate was 102.3/100.000 (95% CI 79,1-132,2), 157.1/100.000 (95% CI 117.5-210.2) in women and 46.3/100.000 (95% CI 27.1-79.2) in men. Women/men ratio was 3.5. Mean age was 44.7±11.1 years, 45.4±11.2 in women and 42.3±10.9 in men. A total of 45 of the 58 patients (77.6%) were treated with disease specific therapies: glatiramer (13.8%), beta-interferon (17.2%), dimethyl-fumarate (17.2%), rituximab/ocrelizumab (12%), fingolimod (8.6%), natalizumab (6.9%), azathioprine (1.7%). MS phenotypes (2013 revisions) were: relapsing remitting MS (RRMS) with activity, 10.3%; RRMS without activity, 69%; secondary progressive MS (SPMS) with progression but without activity, 3.4%; SPMS without progression or activity, 6.9%; primary progressive MS (PPMS) without activity or progression, 3.4%; PPMS with activity and progression, 3.4%; PPMS with progression but without activity, 3.4%.
Conclusions: Our study suggests that the prevalence rate of MS and the women to men ratio is increasing in the southeast of Spain. The revised Lublin criteria for the clinical course gives a more dynamic description of MS phenotypes and should be included in epidemiological studies of MS.
Disclosure:
Natalia Perez-Carmona has received speaker honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva
Leticia Berenguer-Ruiz has received speaker honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva
Cristina Borrego-Honrubia: nothing to disclose
Ramon Gomez-Illan: nothing to disclose
Rosa Garcia-Tercero: nothing to disclose
Angel P Sempere has received compensation for serving on scientific advisory boards or in speaker´s bureaus from Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Roche, Sanofi-Aventis, and Teva.
Abstract: EP1344
Type: ePoster
Abstract Category: Clinical aspects of MS - 5 Epidemiology
Background and objectives: Available epidemiological data suggest that the prevalence of multiple sclerosis (MS) in Spain is progressively increasing during the last four decades. The aim of this study was to estimate the actual prevalence rate of MS in the southeast of Spain.
Methods: This epidemiologic study was conducted in the city of San Vicente del Raspeig, located in the southeast of Spain, latitude 38° 23′, with a population of 56.715. April 10, 2017 was selected as the prevalence day. Case ascertainment included computerised primary care medical records system, the MS database of Alicante General Hospital, the district hospital that offers specialized care to MS patients and data from the MS patients´ association. 2010 McDonald´s criteria were used for the diagnosis of multiple sclerosis. Lublin criteria (2013 revisions) were used for MS phenotypes.
Results: A total of 58 patients (45 women, 13 men) had a confirmed diagnosis (Poser and 2010 McDonald´s criteria). The overall crude prevalence rate was 102.3/100.000 (95% CI 79,1-132,2), 157.1/100.000 (95% CI 117.5-210.2) in women and 46.3/100.000 (95% CI 27.1-79.2) in men. Women/men ratio was 3.5. Mean age was 44.7±11.1 years, 45.4±11.2 in women and 42.3±10.9 in men. A total of 45 of the 58 patients (77.6%) were treated with disease specific therapies: glatiramer (13.8%), beta-interferon (17.2%), dimethyl-fumarate (17.2%), rituximab/ocrelizumab (12%), fingolimod (8.6%), natalizumab (6.9%), azathioprine (1.7%). MS phenotypes (2013 revisions) were: relapsing remitting MS (RRMS) with activity, 10.3%; RRMS without activity, 69%; secondary progressive MS (SPMS) with progression but without activity, 3.4%; SPMS without progression or activity, 6.9%; primary progressive MS (PPMS) without activity or progression, 3.4%; PPMS with activity and progression, 3.4%; PPMS with progression but without activity, 3.4%.
Conclusions: Our study suggests that the prevalence rate of MS and the women to men ratio is increasing in the southeast of Spain. The revised Lublin criteria for the clinical course gives a more dynamic description of MS phenotypes and should be included in epidemiological studies of MS.
Disclosure:
Natalia Perez-Carmona has received speaker honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva
Leticia Berenguer-Ruiz has received speaker honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva
Cristina Borrego-Honrubia: nothing to disclose
Ramon Gomez-Illan: nothing to disclose
Rosa Garcia-Tercero: nothing to disclose
Angel P Sempere has received compensation for serving on scientific advisory boards or in speaker´s bureaus from Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Roche, Sanofi-Aventis, and Teva.